Volume change with gantenerumab: Impact of amyloid-related imaging abnormalities and amyloid removal. | ClinicLens
Amyloid-lowering antibodies are associated with neuroanatomical volume changes. This study aims to disentangle the contributions of amyloid-related imaging abnormalities (ARIA) and amyloid clearance to these changes. Data from the GRADUATE I and II trials of gantenerumab in early
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.